SCHEMBL6134310

SCHEMBL6134310

CC(C)n1nc(-c2cnc(NC(=O)c3ccccc3)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
TP53 P04637 1/20 0.42
ADORA1 P30542 6/20 0.41
MAPK1 P28482 1/20 0.41
ADORA2A P29274 4/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
RCE1 Q9Y256 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
EPHX2 P34913 1/20 0.39
ADORA3 P0DMS8 2/20 0.39
HDAC1 Q13547 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134129 0.94 ADORA2A (0.48) GAACYP1A2CYP3A4CYP2C19TP53
SCHEMBL6134147 0.93 KDM4E (0.48) GAACYP1A2CYP3A4CYP2C19TP53
SCHEMBL6135802 0.93 HTT (0.48) GAACYP1A2CYP3A4CYP2C19TP53
SCHEMBL6133862 0.93 LMNA (0.45) GAACYP1A2CYP3A4CYP2C19TP53
SCHEMBL6133600 0.92 GRM5 (0.43) TP53ADORA1ADORA2AEPHX2ADORA3
SCHEMBL6134239 0.92 KDM4E (0.51) ADORA1ADORA2AKDM4EMAPTALDH1A1
SCHEMBL6133749 0.90 TP53 (0.44) GAATP53ADORA1KDM4EALDH1A1
SCHEMBL6134592 0.89 ADORA1 (0.47) TP53ADORA1ADORA2AMAPTALDH1A1
SCHEMBL6134405 0.88 KDM4E (0.40) TP53ADORA1ADORA2AKDM4EMAPT
SCHEMBL6135441 0.87 POLB (0.47) TP53ADORA1NPC1RAB9ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 GAA 2324/4885CYP1A2 1170/4885CYP3A4 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.